Vera Therapeutics, Inc.
VERA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831828
In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Vera Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 95 | 159 | +64 |
| Shares | 41.4M | 51.3M | +9.87M (+23.8%) |
| Value | $637.2M | $2.21B | +$1.57B (+247.1%) |
New holders (72)
Institutions that held Vera Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (8)
Institutions that held Vera Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Carlyle Group Inc. | 1,438,155 | $22.1M |
| Independent Financial Group, LLC | 87,480 | $1.35M |
| Weiss Multi-Strategy Advisers LLC | 76,224 | $1.17M |
| Gsa Capital Partners LLP | 52,590 | $809.0K |
| ExodusPoint Capital Management, LP | 28,005 | $431.0K |
| Pale Fire Capital SE | 16,389 | $252.1K |
| Balyasny Asset Management LLC | 10,430 | $160.4K |
| Point72 Middle East FZE | 4,927 | $75.8K |